AMA states support for VA telehealth expansion

The American Medical Association (AMA) has released a statement supporting the proposed rule aimed at expanding telehealth services within the Department of Veterans Affairs (VA).

The rule proposed by the VA will change regulations to standardizing the delivery of care through telehealth. VA healthcare providers would be able to give all beneficiaries the same level of care, regardless of state or location of the VA provider. The rule aims to increase access to mental health, specialty and general clinical care to all beneficiaries.

In response, the AMA released the following statement in support of the proposed rule:

“The AMA supports expansion of clinically validated telehealth services within the VA, and this decision ensures that important patient protections are in place for the delivery of high quality and reliable care,” stated Chair-elect of the AMA Board of Trustees Jack Resneck Jr., MD. “The VA has a unique federally controlled healthcare system with essential safeguards to help ensure that both in-person and virtual beneficiary care meet and exceed the standard of care. The AMA strongly supports that the proposed rule explicitly provides that this program’s multi-state licensure exception applies only to VA-employed providers and would not be expanded to contracted physicians or providers who are not directly controlled and supervised by the VA and would not necessarily have the same training, staff support, shared access to a beneficiary’s EHR and infrastructure capabilities. We applaud the VA’s expansion of telehealth services in a manner that promotes quality and access.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.